News from EAS 2024: Long-term data with lomitapide in HoFH

Long term efficacy and safety data of lomitapide in HoFH

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
EAS 2024
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
- Pasquale Perrone-Filardi, MD, PhD
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
EAS 2024
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
- Evan Stein, MD, PhD
Rationale for dietary fat recommendations in ASCVD prevention
Rationale for dietary fat recommendations in ASCVD prevention
EAS 2024
Rationale for dietary fat recommendations in ASCVD prevention
- Jacob J. Christensen, PhD